Document Detail

Idarubicin oral: new formulation. No proven benefit over 60.
MedLine Citation:
PMID:  11067717     Owner:  NLM     Status:  MEDLINE    
(1) Oral idarubicin is marketed in France for the treatment of acute myeloblastic leukaemia in patients over 60 who are ineligible for intensive intravenous treatment. (2) The clinical file on oral idarubicin is limited. (3) In non comparative trials the median survival time after starting treatment with oral idarubicin, alone or combined with other cytotoxic agents, did not exceed 12 months. (4) The only comparative trial of single-agent idarubicin in this indication gave unfavourable results. Another comparative trial tested a combination comprising idarubicin, but the role of idarubicin alone cannot be determined from the results. (5) In the palliative care setting the clinical efficacy of oral idarubicin has not yet been demonstrated. (6) The main adverse events observed during oral idarubicin therapy are neutropenia, thrombocytopenia, nausea and vomiting, diarrhoea and hair loss. Their impact on patients' quality of life has not been adequately assessed.
Related Documents :
8707987 - Rationale of mechanical plaque control.
16307967 - A randomized controlled study comparing 600 versus 1,200 microg oral misoprostol for me...
3330277 - Oral manifestations of systemic chemotherapy and their management.
10358537 - Oral care in the intensive care setting: a case study.
11858687 - Bloodless medicine and surgery for patients having cardiac surgery.
12259737 - Is effectiveness of diaphragm compromised by postcoital swimming or bathing?
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  9     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  2000 Aug 
Date Detail:
Created Date:  2000-10-26     Completed Date:  2000-10-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  103-5     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibiotics, Antineoplastic* / administration & dosage,  adverse effects,  therapeutic use
Clinical Trials as Topic
Drug Approval
Idarubicin* / administration & dosage,  adverse effects,  therapeutic use
Leukemia, Myeloid, Acute / drug therapy*,  mortality
Middle Aged
Survival Rate
Treatment Outcome
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 58957-92-9/Idarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ceftriaxone and otitis in children: new indication. Only in special circumstances.
Next Document:  Pneumococcal vaccination for elderly subjects: license extension. Still no proof of clinical efficac...